Want to see KR:068760 full AI Analyst Report?
Top Page
Celltrion Pharm Inc.
(068760)
Select Model
Select Model
Rating:54Neutral
Price Target:
₩37,281.00
Action:N/A
Date:10/28/26
The score is held back primarily by weak technicals (below key moving averages with negative MACD) and a very high P/E with minimal dividend support. These are partially offset by improving financial performance in 2025 and a de-risking balance sheet, though cash-flow volatility remains a meaningful risk.
Positive Factors
Improving revenue and profitability
The 2025 step-up in revenue, alongside improved EBIT and EBITDA margins, indicates stronger operating scale and healthier recent profitability. If maintained, this combination can support reinvestment and earnings growth while strengthening the economics of the finished-pharmaceutical portfolio over the next several quarters.
Negative Factors
Volatile cash conversion
The history of negative or very low cash flow, together with the 2025 FCF decline despite higher earnings, shows that cash conversion is not consistently dependable. This can constrain internally funded investment and make financial planning more sensitive to operating fluctuations.
Read all positive and negative factors
Positive Factors
Negative Factors
Improving revenue and profitability
The 2025 step-up in revenue, alongside improved EBIT and EBITDA margins, indicates stronger operating scale and healthier recent profitability. If maintained, this combination can support reinvestment and earnings growth while strengthening the economics of the finished-pharmaceutical portfolio over the next several quarters.
Read all positive factors
Celltrion Pharm Inc. (068760) vs. SPDR S&P 500 ETF (SPY)
Market Cap
₩1.60T
Dividend Yield0.42%
Average Volume (3M)68.68K
Price to Earnings (P/E)130.9
Beta (1Y)0.28
Revenue Growth13.88%
EPS Growth29.24%
CountryKR
EmployeesN/A
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)882.94
Shares Outstanding43,683,804
10 Day Avg. Volume59,106
30 Day Avg. Volume68,677
Financial Highlights & Ratios
PEG Ratio1.21
Price to Book (P/B)7.83
Price to Sales (P/S)6.37
P/FCF Ratio49.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Celltrion Pharm Inc. Business Overview & Revenue Model
Company Description
Celltrion Pharm Inc. operates within South Korea's healthcare industry, primarily focusing on the production and distribution of a diverse range of pharmaceutical products. These include heptatonics, pain relievers, fever reducers, anti-inflammato...
Celltrion Pharm Inc. Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
74
Positive
Cash Flow
63
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 536.40B | 477.84B | 388.79B | 386.04B | 398.74B |
| Gross Profit | 163.78B | 122.01B | 119.71B | 112.77B | 119.25B |
| EBITDA | 78.63B | 57.36B | 54.22B | 54.10B | 64.26B |
| Net Income | 38.75B | 21.97B | 21.26B | 25.96B | 34.58B |
Balance Sheet | |||||
| Total Assets | 759.44B | 669.46B | 641.64B | 599.72B | 637.88B |
| Cash, Cash Equivalents and Short-Term Investments | 116.93B | 69.60B | 37.13B | 49.07B | 88.16B |
| Total Debt | 161.31B | 172.17B | 162.53B | 160.70B | 181.03B |
| Total Liabilities | 323.48B | 272.54B | 264.98B | 242.94B | 305.92B |
| Stockholders Equity | 435.96B | 396.92B | 376.67B | 356.79B | 331.97B |
Cash Flow | |||||
| Free Cash Flow | 68.51B | 50.61B | 1.86B | -10.33B | 80.65B |
| Operating Cash Flow | 86.43B | 56.59B | 8.76B | -4.05B | 93.15B |
| Investing Cash Flow | -57.54B | -12.12B | -4.22B | -14.57B | -16.30B |
| Financing Cash Flow | -24.50B | -18.71B | -16.21B | -30.18B | -22.41B |
Celltrion Pharm Inc. Technical Analysis
Negative
―
Price Trends
39721.00
Negative
40579.50
Negative
50493.50
Negative
Market Momentum
-715.73
Positive
40.60
Neutral
16.78
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KR:068760, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 38262.50, equal to the 50-day MA of 39721.00, and equal to the 200-day MA of 50493.50, indicating a bearish trend. The MACD of -715.73 indicates Positive momentum. The RSI at 40.60 is Neutral, neither overbought nor oversold. The STOCH value of 16.78 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KR:068760.
Celltrion Pharm Inc. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | ₩1.17T | 5.97 | ― | 0.59% | 9.87% | 160.28% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
54 Neutral | ₩1.60T | 130.86 | ― | 0.42% | 13.88% | 29.24% | |
49 Neutral | ₩76.86B | -8.16 | ― | ― | -5.10% | 19.68% | |
46 Neutral | ₩324.15B | -55.61 | ― | 2.06% | 15.38% | ― | |
42 Neutral | ₩67.75B | -6.31 | ― | 0.46% | -0.58% | -669.88% | |
40 Underperform | ₩41.40B | -0.23 | ― | ― | 26.13% | 58.75% |
* General Sector Average
KR:068760
Celltrion Pharm Inc.
36,800.00
-24,765.13
-40.23%
KR:003060
Aprogen Biologics
1,380.00
-6,975.00
-83.48%
KR:063160
CKD Bio Corp.
12,350.00
-9,050.00
-42.29%
KR:069620
Daewoong Pharmaceutical Co., Ltd.
101,500.00
-34,729.16
-25.49%
KR:170900
Dong-A ST Co., Ltd.
34,000.00
-10,525.21
-23.64%
KR:183490
Enzychem Lifesciences Corp.
990.00
-24.00
-2.37%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.